Mark S. Schroeder Sells 5,339 Shares of Laboratory Co. of America Holdings (NYSE:LH) Stock

Laboratory Co. of America Holdings (NYSE:LH) COO Mark S. Schroeder sold 5,339 shares of the company’s stock in a transaction dated Friday, February 28th. The shares were sold at an average price of $249.23, for a total transaction of $1,330,638.97. Following the transaction, the chief operating officer now owns 4,960 shares in the company, valued at $1,236,180.80. This represents a 51.84 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Laboratory Co. of America Trading Up 1.2 %

Shares of LH stock opened at $254.01 on Tuesday. The stock has a market capitalization of $21.26 billion, a price-to-earnings ratio of 28.80, a PEG ratio of 1.71 and a beta of 1.07. The company’s fifty day simple moving average is $241.72 and its two-hundred day simple moving average is $232.98. Laboratory Co. of America Holdings has a 1 year low of $191.97 and a 1 year high of $258.59. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.44 and a quick ratio of 1.30.

Laboratory Co. of America (NYSE:LH) last issued its quarterly earnings data on Thursday, February 6th. The medical research company reported $3.45 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.40 by $0.05. Laboratory Co. of America had a return on equity of 15.29% and a net margin of 5.73%. As a group, analysts anticipate that Laboratory Co. of America Holdings will post 16.01 earnings per share for the current year.

Laboratory Co. of America Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, March 12th. Investors of record on Thursday, February 27th will be paid a dividend of $0.72 per share. The ex-dividend date of this dividend is Thursday, February 27th. This represents a $2.88 annualized dividend and a yield of 1.13%. Laboratory Co. of America’s dividend payout ratio is currently 32.65%.

Analysts Set New Price Targets

LH has been the topic of a number of research reports. UBS Group lowered their target price on Laboratory Co. of America from $293.00 to $286.00 and set a “buy” rating on the stock in a research report on Tuesday, January 28th. StockNews.com upgraded Laboratory Co. of America from a “hold” rating to a “buy” rating in a report on Friday, February 7th. Piper Sandler raised their price target on shares of Laboratory Co. of America from $240.00 to $260.00 and gave the company a “neutral” rating in a research report on Monday, February 10th. Morgan Stanley increased their price objective on shares of Laboratory Co. of America from $260.00 to $270.00 and gave the company an “overweight” rating in a research note on Tuesday, December 17th. Finally, Evercore ISI raised Laboratory Co. of America from an “in-line” rating to an “outperform” rating and upped their target price for the company from $260.00 to $265.00 in a report on Tuesday, January 7th. Three analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $268.38.

Institutional Trading of Laboratory Co. of America

Hedge funds and other institutional investors have recently bought and sold shares of the company. Graney & King LLC purchased a new stake in shares of Laboratory Co. of America in the 4th quarter valued at about $26,000. SouthState Corp purchased a new stake in Laboratory Co. of America in the third quarter valued at approximately $28,000. Fortitude Family Office LLC lifted its position in Laboratory Co. of America by 312.5% during the fourth quarter. Fortitude Family Office LLC now owns 132 shares of the medical research company’s stock valued at $30,000 after purchasing an additional 100 shares during the last quarter. Geneos Wealth Management Inc. grew its stake in Laboratory Co. of America by 309.8% in the 4th quarter. Geneos Wealth Management Inc. now owns 168 shares of the medical research company’s stock worth $39,000 after buying an additional 127 shares in the last quarter. Finally, Human Investing LLC bought a new position in shares of Laboratory Co. of America in the 4th quarter worth $39,000. Institutional investors own 95.94% of the company’s stock.

About Laboratory Co. of America

Labcorp Holdings, Inc engages in providing medical testing services. The company was founded on April 16, 2024 and is headquartered in Burlington, NC.